



ILW

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
and
CHANGE OF CORRESPONDENCE
ADDRESS**

Application/Patent Number	10/525,532
Filing/Issue Date	July 25, 2005
First Named Inventor/Patentee	David Cavalla
Confirmation Number	7065
Group Art Unit	1617
Examiner Name	Layla Soroush
Attorney Docket Number	3506.1024-000

Title New Therapeutic Uses of (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ I hereby appoint the following practitioner(s): _____

OR

☒ I hereby appoint the practitioners associated with the Customer Number: **021005**

Please change the correspondence address for the above-identified application to:

☒ **Customer Number 021005**
Hamilton, Brook, Smith & Reynolds, P.C.
530 Virginia Road
P.O. Box 9133
Concord, Massachusetts 01742-9133

☐ Other _____

Please direct all telephone calls and facsimiles to:

Name Susan M. Abelleira, Esq. Tel. No. 978-341-0036 Fax No. 978-341-0136

I am the:

☐ Applicant/Inventor.

☒ Authorized representative of the Assignee, Dynogen Pharmaceuticals, Inc., of the entire interest. See 37 CFR § 3.71. A Statement under 37 CFR § 3.73(b) is enclosed.

☐ Authorized representative of the Assignee, [FILL IN WITH NAME OF ASSIGNEE], together with [FILL IN WITH NAME OF ASSIGNEE], of the entire interest. A Statement under 37 CFR § 3.73(b) is enclosed.

SIGNATURE of Applicant or Assignee of Record

Signature	<u>Mark F. Boshar</u>
Name & Title	Mark F. Boshar, V.P. Legal Affairs and Chief Patent Counsel
Date	<u>Feb. 25, 2008</u>

STATEMENT UNDER 37 CFR § 3.73(b)Applicant/Patentee: David Cavalla and Robert William GristwoodApplication No./Patent No.: 10/525,532Filed/Issue Date: July 25, 2005For: New Therapeutic Uses of (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]PyrimidineDynogen Pharmaceuticals, Inc.

(Name of Assignee)

, a

Corporation

Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above; or
- B. ☐ an assignee together with [] of the entire right, title and interest in the patent application identified above.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☐ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel [], Frame [], or a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventors of the patent application identified above, to the current assignee as shown below:

1. From: David Cavalla and Robert William Gristwood To: Arachnova Ltd.
The document was recorded in the United States Patent and Trademark Office at
Reel 016284, Frames 0959-0960, or a copy thereof is attached.
2. From: David Cavalla and Robert William Gristwood To: Arachnova Therapeutics Ltd.
The document was recorded in the United States Patent and Trademark Office at
Reel 016873, Frames 0433-0435, or a copy thereof is attached.
3. From: Arachnova Therapeutics, Inc. To: Dynogen Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 020409, Frames 0077-0085, or a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Name: Mark F. BosharTitle: V.P. Legal Affairs and Chief Patent Counsel

Date:

Feb. 25, 2008